NCT05199753View on ClinicalTrials.gov

Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

LM-108

Administered intravenously

DRUG

An Anti-PD-1 Antibody

Administered intravenously

Trial Locations (6)

NSW 2148

Blacktown Hospital, Sydney

QLD 4575

Sunshine Coast University Private Hospital, Birtinya

QLD 4101

ICON Cancer Centre, South Brisbane

VIC 3144

Cabrini Health Limited, Malvern

VIC 3004

Alfred Hospital, Melbourne

WA 6009

One Clinical Research Pty Ltd., Nedlands

All Listed Sponsors
lead

LaNova Australia Pty Limited

INDUSTRY